Publications by authors named "Lilly East"

Claim this Profile
S
State-of-the-Art on Model-Informed Drug Development Approaches for Pediatric Rare Diseases.
Rajesh Krishna, Amitava Mitra, Matthew L Zierhut, Lilly East, Chandra Durairaj

CPT Pharmacometrics Syst Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacodynamic Evaluation of Bidridistrogene Xeboparvovec in an Aged Murine Model of Limb-Girdle Muscular Dystrophy Type 2E/R4.
Stephen Baine, Jared Cui, Young-Eun Seo, Amber Kempton, Oliver Rogers, Lilly East

Hum Gene Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population.
Yogesh Patel, Larry Orogun, Nicole Yocum, Louise R Rodino-Klapac, Lilly East

CPT Pharmacometrics Syst Pharmacol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy.
Andrew K L Goey, Marie Claire Mukashyaka, Yogesh Patel, Louise R Rodino-Klapac, Lilly East

Drug Metab Dispos· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen': Neuromuscular Disorders 31 (2021) 310-318/doi: 10.1016/j.nmd.2021.02.014.
Drew MacCannell, Zdenek Berger, Lilly East, Eugenio Mercuri, Janbernd Kirschner

Neuromuscul Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
Kathryn R Wagner, Nancy L Kuntz, Erica Koenig, Lilly East, Sameer Upadhyay

Muscle Nerve· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen.
Drew MacCannell, Zdenek Berger, Lilly East, Eugenio Mercuri, Janbernd Kirschner

Neuromuscul Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Pedro Cahn, Richard Kaplan, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Lilly East

Lancet HIV· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.
Rajesh Krishna, Lilly East, Patrick Larson, Tara Siringhaus, Lisa Herpok

Biopharm Drug Dispos· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.
Rajesh Krishna, Lilly East, Patrick Larson, Chandni Valiathan, Kathleen Deschamps

Biopharm Drug Dispos· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
Rajesh Krishna, Lilly East, Patrick Larson, Chandni Valiathan, Kristin Butterfield

J Pharm Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis